v3.25.4
Income Taxes
12 Months Ended
Dec. 31, 2025
Income Tax Disclosure [Abstract]  
Income Taxes

11. Income Taxes

For the years ended December 31, 2025 and 2024, the Company recorded income tax benefit of $6,162 and income tax expense of $925, respectively. The net benefit was primarily the result of recognition of previously unrecognized tax benefits following a lapse in the statute of limitations.

The provision (benefit) for income taxes consists of the following:

 

 

 

Year Ended December 31,

 

 

 

2025

 

 

2024

 

Current tax expenses (benefit)

 

 

 

 

 

 

US Federal

 

$

(6,207

)

 

$

613

 

US State

 

 

45

 

 

 

312

 

Total current tax expense (benefit)

 

 

(6,162

)

 

 

925

 

Deferred tax expense (benefit)

 

 

 

 

 

 

US Federal

 

 

 

 

 

 

US State

 

 

 

 

 

 

Total deferred tax expense (benefit)

 

 

 

 

 

 

Total income tax expense (benefit)

 

 

 

 

 

 

US Federal

 

 

(6,207

)

 

 

613

 

US State

 

 

45

 

 

 

312

 

Total provision (benefit) for income taxes

 

$

(6,162

)

 

$

925

 

As further described in Note 2, Summary of Significant Accounting Policies, the Company has elected to prospectively adopt the guidance in ASU 2023-09. The following table is a reconciliation of the Company's effective income tax rate to the statutory federal income tax rate for the year ended December 31, 2025 in accordance with the guidance in ASU 2023-09:

Year Ended December 31, 2025

At statutory rate

 

$

(34,547

)

 

 

21.00

 

%

State income taxes, net of federal effect

 

 

150

 

 

 

(0.10

)

 

Change in valuation allowance

 

 

36,562

 

 

 

(22.22

)

 

Nontaxable or nondeductible items

 

 

 

 

 

 

 

Stock-based compensation

 

 

2,471

 

 

 

(1.50

)

 

Other nontaxable or nondeductible items

 

 

21

 

 

 

(0.01

)

 

Changes in tax laws or rates

 

 

 

 

 

 

 

Federal R&D credits

 

 

(4,607

)

 

 

2.80

 

 

Cross-border tax laws

 

 

 

 

 

 

 

Worldwide changes in unrecognized tax benefits

 

 

(6,356

)

 

 

3.86

 

 

Other

 

 

144

 

 

 

(0.09

)

 

Total

 

$

(6,162

)

 

 

3.74

 

%

The following table is a reconciliation of the Company's effective income tax rate to the statutory federal income tax rate for the year ended December 31, 2024 in accordance with the guidance prior to the adoption of ASU 2023-09:

Year Ended December 31, 2024

Expected income tax benefit at the federal statutory rate

 

21.0

%

State and local taxes

 

4.4

 

Research and development credits

 

3.5

 

Stock-based compensation

 

(3.9)

 

Uncertain tax positions

 

(0.4)

 

Other

 

0.5

 

Change in valuation allowance

 

(25.7)

 

Total

 

(0.6)

%

 

In 2025 and 2024 state and local income taxes in Massachusetts comprise the majority of the state and local income taxes, net of federal effect category. Income taxes paid to Massachusetts in 2025 were $210.

Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The principal components of the Company’s deferred tax assets consisted of the following:

 

 

 

As of December 31,

 

 

 

2025

 

 

2024

 

Deferred tax assets (liabilities)

 

 

 

 

 

 

Capitalized research and development

 

$

58,533

 

 

$

56,255

 

Net operating loss carryforwards

 

 

56,408

 

 

 

19,514

 

License agreement

 

 

4,726

 

 

 

5,162

 

Stock-based compensation

 

 

23,934

 

 

 

22,681

 

Research and development credits

 

 

18,938

 

 

 

13,959

 

Other

 

 

266

 

 

 

232

 

Prepaid expenses

 

 

(477

)

 

 

(589

)

Deferred tax assets (liabilities)

 

 

162,328

 

 

 

117,214

 

Less: valuation allowance

 

 

(162,328

)

 

 

(117,214

)

Net deferred tax assets (liabilities)

 

$

 

 

$

 

 

As required by the 2017 Tax Cut and Jobs Act, effective January 1, 2022, taxpayers could no longer immediately expense qualified research and development expenditures. Per the One Big Beautiful Bill Act, effective July 4, 2025, taxpayers are still required to capitalize foreign research and development expenditures, but now have the opportunity to deduct domestic research and development expenditures under IRC 174A. Further, the Company has elected to continue to amortize prior year domestic capitalized costs until the amortization of such costs is complete.

As of December 31, 2025, the Company had federal net operating losses of $202,771 and state net operating loss carryforwards of $219,340, which may be used to offset future tax liabilities. The Company has federal and state credit carryforwards of $17,377 and $1,976, respectively. The federal net operating losses and research and development tax credits begin to expire in 2034.

Management has evaluated the positive and negative evidence bearing up the realizability of the Company’s deferred tax assets. Based on the Company’s projected net operating losses, for 2026 and beyond, the Company determined that it is more likely than not that it will not recognize the benefits of the deferred tax assets. As a result, the Company has recorded a full valuation allowance of approximately $162,328 at December 31, 2025.

As required under ASU 2023-09, the Company has included only the portion of the valuation allowance related to federal deferred tax assets in the "change in valuation allowance" line of the rate reconciliation.

The following table presents a reconciliation of the total change in the valuation allowance for the year ended December 31, 2025:

 

Year Ended December 31, 2025

 

Beginning balance

 

$

117,214

 

Changes charged to income tax expense

 

 

45,114

 

Ending balance

 

$

162,328

 

Under the provisions of Sections 382 and 383 of the Internal Revenue Code (“IRC”), net operating loss and credit carryforwards and other tax attributes may be subject to limitation if there has been a significant change in ownership of the Company, as defined by the IRC.

The Company performed an analysis for the years ended December 31, 2025 and 2024 pursuant to Section 382 of the IRC to determine whether any limitations might exist on the utilization of net operating losses and other tax attributes. Based on this analysis, the Company has determined that there was no impact on the Company's ability to utilize net operating losses or credit carryforwards. To the extent that the Company raises additional equity financing or other changes in the ownership interest of significant stockholders occurs, tax attributes may become subject to an annual limitation. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities.

The Company files federal and various state income tax returns. The statute of limitations for assessment by the Internal Revenue Service (“IRS”), and state tax authorities remains open for the tax year ended December 31, 2014 and tax years ending after December 31, 2021. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the IRS or state tax authorities to the extent utilized in a future period. No federal or state tax audits are currently in process.

The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information.

The following table summarizes the reconciliation of the beginning and ending amount of total unrecognized tax benefits for the year ended December 31, 2025:

 

Year Ended December 31, 2025

 

Balance at beginning of year

 

$

6,356

 

Reduction related to accrued interest

 

 

(1,353

)

Lapses in statutes of limitations

 

 

(5,003

)

Balance at end of period

 

$